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Targeting aspirin in acute disabling ischemic stroke: an individual patient data
meta-analysis of three large randomized trials
Douglas D. Thompson1*, Gordon D. Murray1, Livia Candelise2, Zhengming Chen3,
Peter A. G. Sandercock1,4, and William N. Whiteley1,4
Background Aspirin is of moderate overall benefit for patients
with acute disabling ischemic stroke. It is unclear whether
functional outcome could be improved after stroke by target-
ing aspirin to patients with a high risk of recurrent thrombosis
or a low risk of haemorrhage.
Aims Weaimed to determinewhether patients at higher risk of
thrombotic events or poor functional outcome, or lower risk of
major haemorrhage had a greater absolute risk reduction of
poor functional outcomewith aspirin than the average patient.
Methods We used data on individual ischemic stroke patients
from three large trials of aspirin vs. placebo in acute ischemic
stroke: the first International Stroke Trial (n = 18 372), the
Chinese Acute Stroke Trial (n = 20 172) and the Multicentre
Acute Stroke Trial (n = 622). We developed and evaluated clini-
cal prediction models for the following: early thrombotic
events (myocardial infarction, ischemic stroke, deep vein
thrombosis and pulmonary embolism); early haemorrhagic
events (significant intracranial haemorrhage, major extracra-
nial haemorrhage, or haemorrhagic transformation of an
infarct); and late poor functional outcome. We calculated the
absolute risk reduction of poor functional outcome (death or
dependence) at final follow-up in: quartiles of early throm-
botic risk; quartiles of early haemorrhagic risk; and deciles of
poor functional outcome risk.
Results Ischemic stroke patients who were older, had lower
blood pressure, computerized tomography evidence of infarct
or more severe deficits due to stroke had increased risk of
thrombotic and haemorrhagic events and poor functional
outcome. Prediction models built with all baseline variables
(including onset to treatment time) discriminated weakly
between patients with and without recurrent thrombotic
events (area under the receiver operating characteristic curve
0·56, 95% CI:0·53–0·59) and haemorrhagic events (0·57, 0·52–
0·64), though well between patients with and without poor
functional outcome (0·77, 0·76–0·78) in the International
Stroke Trial. We found no evidence that the net benefit of
aspirin increased with increasing risk of thrombosis, haemor-
rhage or poor functional outcome in all three trials.
Conclusions Using simple clinical variables to target aspirin to
patients after acute disabling stroke by risk of thrombosis,
haemorrhage or poor functional outcome does not lead to
greater net clinical benefit. We suggest future risk stratifica-
tion schemes include new risk factors for thrombosis and
intracranial haemorrhage.
Key words: individual patient data meta-analysis, prediction, randomized
clinical trials, stratified treatment, stroke
Background
For the majority of ischemic stroke patients who are not currently
eligible for intravenous thrombolysis, more effective approaches
are needed to further reduce the risk of poor functional outcome.
Early aspirin is an established treatment for disabling ischemic
stroke, but is only modestly effective in reducing death or depen-
dence. For the average stroke patient, it reduces the risk of poor
functional outcome (death or dependence) a fewmonths after the
stroke by about 1% (1). The net clinical benefit with early aspirin
treatment is probably as a result of a favorable balance of a greater
reduction of thrombotic events than an increase in extra- and
intra-cranial haemorrhage. Therefore, the balance between the
risk of haemorrhagic and thrombotic events with antiplatelets is
an attractive target for a better treatment strategy for patients
with acute disabling stroke.
More intensive antiplatelet regimes have not proved more
effective than aspirin in acute disabling stroke. For example,
GpIIb/IIIa inhibitors do not lead to an improvement in functional
outcome compared to aspirin alone, perhaps because they
increase the risk of intracranial haemorrhage. However, when
clopidogrel and aspirin were targeted to Chinese patients with a
particularly high risk of recurrent ischemic stroke, and low risk of
haemorrhage – patients with recent TIA – the more intensive
regime led to a net clinical benefit: fewer ischemic strokes, with no
increase in intracranial haemorrhage (2). This hypothesis is of
great interest in recent TIA, and being explored in different popu-
lations (Platelet Orientated Inhibition in New TIA, POINT,
NCT00991029) and with more intensive antiplatelet regimes
(Triple Antiplatelets for Reducing Dependence After Ischaemic
Stroke, TARDIS, ISRCTN47823388).
We aimed to test the hypothesis that targeting of early
antiplatelet agent on patients with a higher predicted risk of
thrombosis, a lower predicted risk of haemorrhage, or a higher
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predicted risk of poor functional outcome leads to a lower risk of




We identified trials of aspirin vs. placebo or control in acute
ischemic stroke using the latest Cochrane review of antiplatelet
for acute ischemic stroke (1). We excluded two small trials (one
unpublished) which recruited a total of 521 patients between
them, as we were unable to obtain individual patient data (3,4).
We used individual patient data from the largest randomized
trials of aspirin vs. control in acute ischemic stroke patients: the
International Stroke Trial (IST), the Chinese Acute Stroke Trial
(CAST) and the Multicentre Acute Stroke Trial (MAST) (5–7).
Although old, these three trials have the overwhelming majority
of the randomized evidence on aspirin vs. placebo in acute isch-
emic stroke. We excluded patients where the stroke at random-
ization was due to intracranial haemorrhage.
Definition of baseline characteristics and outcomes
We used baseline characteristics common to all trials with the
definitions from each trial. We measured impairment due to
stroke as: a weakness of arm or leg; the presence of aphasia;
hemianopia; visuospatial disorder; and brainstem or cerebellar
deficits. The remaining variables were: patient age, systolic blood
pressure (SBP), presence of atrial fibrillation, delay from stroke to
randomization in hours, and evidence of infarct on computerized
tomography (CT).
We defined two early outcome events: ‘thrombotic events’
[deep vein thrombosis (DVT), pulmonary embolus (PE), isch-
emic stroke, and myocardial infarction (MI)] and ‘haemorrhagic
events’ (significant intracranial haemorrhage, major extracranial
haemorrhage, or haemorrhagic transformation of an infarct) as
close as possible to 14 days after stroke. In IST events in hospital
were recorded at 14 days, in MAST up to 10 days, and in CAST we
restricted analysis to 14 days post randomization. We defined
‘poor functional outcome’ at final follow-up as: a modified
Rankin scale score of 3–6 in MAST; being either dead or respond-
ing ‘yes’ to the question ‘did you need help from another person to
perform everyday activities within the last two weeks?’ in IST; or
as dead or dependent at discharge in CAST. Additionally, we
defined an ordinal outcome scale which was common across each
trial. Both IST and CAST used a similar measurement of func-
tional recovery at the end of follow-up; we mapped the mRS used
in MAST onto this common scale (see Table S1).
IST and MAST measured functional outcome at six-months
and CAST at 28 days.We made no specific allowance for differing
follow-up times as we made within-study comparisons of the
proportion of patients with poor functional outcome at the end
of follow-up.
Model development: predicting benefit and harm
We defined baseline risk of short term adverse outcomes with
clinical prediction models.
We used a non-random split of the IST trial data to develop and
internally evaluate new clinical prediction models since a random
split would yield overly optimistic measures of performance (8).
We developed models in patients recruited to UK and Italian
centers and evaluated them in the patients recruited in the
remaining 34 countries. We developed three multivariable binary
logistic regression models: the first to predict thrombosis within
14 days in patients allocated to control; the second to predict
haemorrhage in those allocated to aspirin; and the third to predict
poor functional outcome at final follow-up in those allocated to
control. We did not try to reduce the number of variables using
data dependent methods as few clinical variables were common to
all trials and all of these were plausibly associated with each
outcome. We assessed linearity and additivity using: restricted
cubic splines (knots 3, 4 and 5) and two-way interactions. We
measured an improvement in model fit when assessing linearity
and additivity as an increase in the Akaike’s Information Crite-
rion (AIC) on the chi-squared scale which simultaneously penal-
izes for the added complexity (9,10).We imputed missing data to
generate multiple datasets (m = 20) since a complete case analyses
can result in a reduction of statistical power and biased estimates
(10).
Model evaluation
We calculated two measures of model performance: ‘calibration’
and ‘discrimination’ (10). Calibration summarizes how well the
observed events match the predicted events by dividing the cohort
into groups of predicted risk and comparing the mean predicted
risk with the observed frequency. We calculated the calibration
slope and intercept as measures of calibration (where slope 1 and
intercept 0 indicates a perfectly calibratedmodel). Discrimination
summarizes how well a model separates patients with the event
from those without. We calculated the area under the receiver
operating characteristic curve (AUROCC) which ranges from no
better than chance (0·5) to perfect (1·0) as a measure of discrimi-
nation. We pooled measures of performance within the evalua-
tion split across the 20 multiply imputed sets (11).
Estimating treatment effects in different risk groups
We defined risk groups of patients by quarters of predicted
thrombotic risk and quarters of predicted haemorrhagic risk.
New patient populations often differ from the model derivation
data; as a consequence predicted risks may be inaccurate. To
account for this, we adopted a simple updating procedure adjust-
ing for any observed differences in outcome incidence between
trials (12). In each of the risk groups we pooled estimates of the
absolute risk reduction of poor functional outcome across the
three trials using the Mantel–Haenszel meta-analytical method.
We examined the effect of aspirin in ten groups of patients
defined by tenths of predicted risk of poor functional outcome
and calculated the observed absolute risk reduction of poor func-
tional outcome within each stratum. We contrast this empirical
effect with the theoretical effect obtained under the assumption
that there is no interaction between treatment with aspirin and
the control event rate. Here the individualized reduction in risk
equals the absolute predicted risk for the patient on control mul-
tiplied by the relative constant treatment effect from aspirin (13).
Finally, because a dichotomized outcome risks losing power, we
calculated the relative effect of aspirin on functional outcome
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measured on a common ordinal scale with ordinal logistic regres-
sion, and looked for a difference in treatment effect by continuous
predicted risk on the log odds scale with multiplicative inter-
action terms between aspirin and the predicted risks of
haemorrhage, thrombosis and poor functional outcome.We per-
formed a sensitivity analysis excluding those patients randomized
to streptokinase or high dose heparin, as these agents may
increase the risk of haemorrhage in combination with aspirin and
are not widely used in acute ischaemic stroke. We additionally
excluded venous thrombotic events from our definition of an
early thrombotic event to assess what impact this had on our
results.
We used R version 3.0.1 for statistical analysis. Design and
conduct of the study; collection,management, analysis, and inter-
pretation of the data; preparation, review, or approval of the
manuscript; and decision to submit the manuscript for publica-
tion was conducted independently from the study funders.
Results
We obtained individual patient data from three trials of aspirin vs.
control on a total of 39 166 patients with acute ischemic stroke.
The design features of each trial, baseline patient characteristics
and outcomes in follow-up are summarized online (see
Tables S2–S4). The proportion of patients with outcome events
differed by trial: in IST 6·1% of patients had a thrombotic event
and 1·4% had a haemorrhagic event; the corresponding propor-
tions in CAST were 1·9% and 1·0% and in MAST 1·6% and 5·8%.
About two-thirds of patients in IST (62·1%) and MAST (63·7%)
had a poor functional outcome by six-months, and about a third
of patients in CAST (30·8%) had poor functional outcome by 28
days. With aspirin, the absolute reduction in thrombotic events
across trials was 6 per 1000 (95% CI 3 to 10, P = 0·0004,
Phet = 0·0123), the absolute increase in haemorrhagic events
across trials was 5 per 1000 (95% CI: 3 to 7, P < 0·0001,
Phet = 0·4666) and the absolute reduction in poor functional
outcome by six-months across trials was 12 per 1000 (95% CI 2 to
21, P = 0·0135, Phet = 0·9193). See Fig. S1 for the associated forest
plots. A similar proportion of patients had a poor functional
outcome after a haemorrhagic event (446/550, 88%) and a throm-
botic event (1353/1534, 88%) by last follow-up. Median time to
death was the same in patients with a thrombotic event (seven-
days, IQR 3 to 12) and with haemorrhagic event (seven-days, IQR
3 to 11).
Prediction of 14-day events after acute
ischemic stroke
We used multivariable logistic regression to model 14-day throm-
bosis using all available baseline variables (Table 1). Only increas-
ing age (OR: 1·21 per decade, 95% CI: 1·07 to 1·38) and the
presence of a CT visible infarct (OR 1·52, 95% CI: 1·17 to 1·98)
were associated significantly with increased risk of thrombotic
events in the model. The final model using all baseline variables
discriminated poorly between patients with and without 14-day
thrombosis (AUROCC 0·56, 95% CI 0·53 to 0·59) and was poorly
calibrated (calibration slope 0·46, 95% CI: 0·33 to 0·60) (Table 2)
in the evaluation split. There was no evidence of deviations from
linearity.
A multivariable logistic regression for 14-day haemorrhage
(Tables 1 and 2) discriminated poorly between those with and
those without 14-day haemorrhage (AUROCC 0·57 with 95% CI
0·52 to 0·64) and was poorly calibrated (calibration slope 0·52,
95% CI: 0·26 to 0·78) in the evaluation split. Although no one
factor was significantly associated with haemorrhage at 14 days in
the final model, the size and direction of all associations were
Table 1 Multivariable prediction models for 14-day events and six-month death or dependency in the development split with imputed IST data (over
20 imputed sets)
Variable
14-day events Six-month outcome
Thrombosis (291/4504) Haemorrhage (74/4511) Dead or dependent (3225/4504)
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Age (per 10 years)
Age 1·21 (1·07 to 1·38) 0·0027 1·24 (0·97 to 1·58) 0·086 0·44 (0·25 to 0·79) 0·0063
Age2 – – – – 1·10 (1·05 to 1·15) < 0·0001
SBP (per 10 mmHg)
SBP 0·98 (0·93 to 1·02) 0·30 0·98 (0·90 to 1·08) 0·74 0·69 (0·53 to 0·91) 0·0083
SBP2 – – – – 1·01 (1·00 to 1·02) 0·0058
Delay from randomization (hours) 0·99 (0·98 to 1·00) 0·064 1·00 (0·98 to 1·01) 0·64 1·00 (1·00 to 1·01) 0·20
Gender (Male) 1·22 (0·95 to 1·57) 0·11 1·46 (0·90 to 2·37) 0·12 0·72 (0·62 to 0·84) < 0·0001
Visible infarct on CT 1·52 (1·17 to 1·98) 0·0019 1·12 (0·66 to 1·90) 0·68 1·05 (0·89 to 1·25) 0·56
Conscious (Drowsy/Coma vs. Alert) 0·97 (0·71 to 1·34) 0·86 1·00 (0·54 to 1·86) 0·99 4·48 (3·36 to 5·98) < 0·0001
Presence of atrial fibrillation 1·18 (0·88 to 1·60) 0·27 1·24 (0·67 to 2·30) 0·49 1·11 (0·89 to 1·38) 0·33
At least one or more of arm/leg deficits 1·54 (0·99 to 2·39) 0·056 1·36 (0·56 to 3·28) 0·49 2·58 (2·08 to 3·19) < 0·0001
Presence of aphasia 1·03 (0·79 to 1·33) 0·84 0·70 (0·42 to 1·15) 0·16 1·44 (1·24 to 1·69) < 0·0001
Presence of hemianopia 1·17 (0·81 to 1·69) 0·39 1·40 (0·68 to 2·86) 0·36 2·06 (1·59 to 2·67) < 0·0001
Presence of visuospatial disorder 1·11 (0·77 to 1·60) 0·58 1·04 (0·52 to 2·06) 0·92 1·83 (1·41 to 2·38) < 0·0001
Presence of brainstem/cerebellar deficit 1·41 (0·95 to 2·09) 0·092 0·71 (0·28 to 1·84) 0·48 0·83 (0·66 to 1·06) 0·15
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similar to those for thrombotic events. There was no evidence of
deviation from linearity.
Prediction of six-month poor functional outcome after
acute ischemic stroke
A multivariable binary logistic regression to predict six-month
poor functional outcome discriminated well (AUROCC 0·77,
95% CI 0·76 to 0·78) and had good calibration (calibration
slope 0·90 and intercept −0·75) in internal evaluation (Tables 1
and 2). The model had similar discrimination in the CAST
(0·71, 95% CI: 0·70 to 0·72) and MAST trials (0·76, 95% CI: 0·70
to 0·81). Markers of increasing impairment due to stroke (arm/
leg weakness, aphasia, hemianopia, visuospatial disorder and
unconscious or drowsy at randomization) were associated
with a statistically significant increase in the risk of poor
functional outcome. The inclusion of a squared term for both
age [Likelihood Ratio (LR) test with a P-value < 0·0001] and
blood pressure (LR test P-value = 0·0004) resulted in a signifi-
cant improvement in the prediction of poor functional
outcome.
Absolute benefit or harm of aspirin across strata of
predicted risk
We defined strata of patients by quarters of predicted risk of
thrombotic and haemorrhagic events on updated predictions (see
Table S5). In no group was there a statistically significant increase
in the risk of poor outcome with aspirin treatment compared to
control.No trend of harm or benefit with aspirin was evident with
increasing thrombotic or haemorrhagic risk (see Fig. S2 and
Fig. 1). We plotted the risk of thrombotic events vs. the risk of
haemorrhagic events in control and aspirin arms for IST (see
Fig. S3 and Fig. 2). This figure demonstrates the correlation
between haemorrhagic and thrombotic risk. There was no evi-
dence that those with a high haemorrhagic risk and a low throm-
botic risk were harmed by aspirin, nor was there evidence that
those with a low haemorrhagic risk and high thrombotic risk
benefitted any more than the average estimate of 1% reduction in
poor functional outcome (though there were very few patients in
these groups). In no risk group of haemorrhage or thrombotic
events was the absolute reduction in poor functional outcome at
final follow-up statistically different from the overall estimate of
Table 2 Performance of prediction models in evaluation split with imputed IST data (over 20 imputed sets) for prediction models
Measure Thrombosis (on control) Haemorrhage (on aspirin) Dead or dependent (on control)
Events/Total 337/4685 87/4672 2587/4685
r2 (%) (IQR) 0·58 (0·55 to 0·59) 0·57 (0·39 to 0·67) 28·58 (28·46 to 28·82)
AUROCC 0·56 (0·53 to 0·59) 0·57 (0·52 to 0·64) 0·77 (0·76 to 0·78)
Calibration
Intercept 0·14 (0·09 to 0·20) 0·20 (0·094 to 0·31) −0·75 (−0·78 to −0·71)
Slope 0·46 (0·33 to 0·60) 0·52 (0·26 to 0·78) 0·90 (0·87 to 0·93)
Cell entries are estimates and 95% CI unless otherwise stated.
Fig. 1 Pooled estimates of absolute risk reduction (ARR) in poor outcome. Q1 to Q4 denote quarters of risk defined on IST data. Square sizes are
proportional to the strata specific denominator. Data from IST contributed to all within strata estimates, CAST contributed to most and MAST contributed
to only one. Note that: No. Studies, number of studies; n, number of outcomes; and N, total number of patients.
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1% (95% CI: 0% to 2%, P = 0·0135, Phet = 0·9193 between
groups). In a sensitivity analysis, we excluded patients from
MAST randomized to streptokinase and from IST randomized to
high dose heparin. This made no major difference to these results.
Excluding venous thrombotic events from our analysis made no
qualitative difference to our findings.
In tenths of increasing predicted risk of poor functional
outcome, there was no suggestion that patients with higher pre-
dicted risk of poor functional outcome had a greater or lesser
benefit from aspirin than the overall estimate of 1% (estimated
slope through pooled estimates was 0·01 with 95% CI −0·05 to
0·08, Fig. 3). Models which assumed a fixed absolute risk reduc-
tion of 1% or a constant OR of 1·06 with treatment fitted the data
equally well. Using a more statistically efficient ordinal analysis
modeling risk continuously, there was no evidence that the pre-
dicted risk of thrombosis and haemorrhage (P = 0·2244) or poor
functional outcome (P = 0·3968) interacted with aspirin on poor
functional outcome.
Fig. 2 Predicted risk of thrombosis vs. predicted risk of haemorrhage in IST. Horizontal and vertical grey lines indicate quarters of risk. Grey points indicate
patient dead or dependent and black alive and independent. To aid visualisation a simple random sample of 2000 patients is shown.
Fig. 3 Meta-analysis of predicted risk of poor outcome (in tenths, defined on IST data) across all three trials pooled using fixed-effects meta-analysis.
Square sizes are proportional to the strata specific denominator. Fitted line had a slope (solid line) that was no different from zero (P = 0·6562) and no
different from the theoretical slope (dashed line) of 0·06 (P = 0·1588). The dotted line and grey band represents the overall ARR estimate. In all but the
seventh decile was there significant between trial heterogeneity (P = 0·0245).
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Discussion
We developed and validated a reliable method to predict poor
functional outcome in patients randomized to the three largest
trials of aspirin therapy in acute ischemic stroke. However, there
was no evidence that patients with higher predicted risks of poor
functional outcome had a different response to early aspirin
treatment than patients at a lower risk either on an absolute or
relative scale. As our models for thrombotic and haemorrhagic
events performed poorly, we were unable to identify reliably
those patients at a lower risk of post-stroke haemorrhage or
higher risk of recurrent thrombotic events, who might be
expected to benefit more than average from treatment with early
aspirin. Using the methods we developed, there was no evidence
that patients at higher predicted risk of either haemorrhage or
thrombosis responded differently to aspirin than patients at a
lower risk.
Our study had a number of methodological strengths: we ana-
lyzed almost all the patients randomized to early aspirin vs.
control in acute stroke trials; we modeled harms and benefits
separately; we used an outcome measuring disability, rather than
just events, so avoiding problems assigning weight to events of
different severities; we did not implicitly assume linearity or addi-
tivity in our clinical prediction models; we accounted for missing
data using multiple imputation avoiding the potential biases of a
complete case analysis; we left continuous predictors continuous;
and finally, we did not remove insignificant predictors in our
models or screen predictors at a univariate level, which would risk
the problems with data-dependent selection (14). A previous
meta-analysis did not consider the risk and benefits of treatment
separately, nor data from the MAST trial (15). While a similar
analysis in routinely collected data would add more patients and
therefore yield greater statistical power the conclusions from such
a study would be limited by the selection biases associated with
the decision to treat or not treat individual patients.
Our study had a number of limitations. We used data from
pragmatic trials, where the primary aim was detection of func-
tional outcome at final follow-up, therefore the trials probably
under ascertained thrombotic and haemorrhagic events; to miti-
gate this limitation we developed and tested models for the
thrombotic and haemorrhagic outcome in the IST trial, where the
number of reported events was consistent with contemporary
literature reports of post stroke complications (16). In addition,
these outcomes were not adjudicated in IST or CAST. It is plau-
sible that relative effects of early aspirin on the risk of haemor-
rhage are different in patients randomized to heparin or
streptokinase compared to patients not on these medications.We
therefore excluded, in a secondary analysis, participants random-
ized to these treatments which made no difference to the magni-
tude or direction of our results. However, as this secondary
analysis did not examine patients in their randomized groups, the
causal inferences that can be drawn from it are limited. We had
limited sensitivity for the effect of stroke severity on thrombotic
or haemorrhagic risk, as the trials measured impairment by
counting relatively crude deficits, rather than using a more sensi-
tive scale such as the National Institutes of Health Stroke Scale.We
were unable to test other plausible variables that might discrimi-
nate between thrombotic or haemorrhagic events, because they
were not recorded in these very large pragmatic trials, for
example: previous gastrointestinal ulceration, prior DVT, cancer,
cerebral microbleeds, more advanced brain imaging findings or
physiological or genetic markers of aspirin metabolism. Better
prediction models constructed using these variables might better
identify patients who are at a higher risk of bleeding, but they
would need to be implemented in new trials of antiplatelet agent
in acute stroke in order to determine whether they predicted net
clinical benefit or harm from treatment.
The risk of poor functional outcome at final follow-up was the
same (88%) in patients with a haemorrhagic complication to
patients with a thrombotic complication. This is similar to acute
coronary syndromes, where bleeding and recurrent thromboses
have similar mortality (11% with recurrent MI and 12% with
bleeding) (17). However, in contrast to acute coronary syn-
dromes, where thrombosis increases mortality in the short term
and haemorrhage increases mortality in the longer term, in acute
stroke, short term mortality was increased by both events (18).
Conclusions
Contrary to expectations, we found no evidence to support a
stratified approach to early aspirin treatment in acute ischemic
stroke patients according to the predicted risks of poor functional
outcome, thrombosis or haemorrhage. Early aspirin is therefore
an important part of treatment for all patients with acute dis-
abling ischaemic stroke.
Our results do not suggest that the net clinical benefit of new
acute antiplatelet regimes in acute disabling stroke will vary across
subgroups defined by combinations of simple clinical variables. It
is likely that such trials will need to use newer measures of the risk
of thrombosis and intracranial haemorrhage in order to explore
important treatment effects.
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